These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 21270261)

  • 1. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
    Jeong HW; Lee JW; Kim WS; Choe SS; Kim KH; Park HS; Shin HJ; Lee GY; Shin D; Lee H; Lee JH; Choi EB; Lee HK; Chung H; Park SB; Park KS; Kim HS; Ro S; Kim JB
    Diabetes; 2011 Feb; 60(2):496-506. PubMed ID: 21270261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
    Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
    Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
    Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
    Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
    Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Jung HY; Kim B; Ryu HG; Ji Y; Park S; Choi SH; Lee D; Lee IK; Kim M; Lee YJ; Song W; Lee YH; Choi HJ; Hyun CK; Holzapfel WH; Kim KT
    Diabetes Obes Metab; 2018 Jul; 20(7):1688-1701. PubMed ID: 29516607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
    Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
    Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
    Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
    Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
    Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
    Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.
    Park MH; Park JY; Lee HJ; Kim DH; Park D; Jeong HO; Park CH; Chun P; Moon HR; Chung HY
    PLoS One; 2013; 8(11):e78815. PubMed ID: 24244369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.
    Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T
    J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro.
    Ren T; Yang WS; Lin Y; Liu JF; Li Y; Yang LC; Zeng KY; Peng L; Liu YJ; Ye ZH; Luo XM; Ke YJ; Diao Y; Jin X
    Eur J Pharmacol; 2018 May; 826():1-8. PubMed ID: 29476879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J; Miao JJ; Sun XY; Yu JY
    J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice.
    Lee W; Ham J; Kwon HC; Kim YK; Kim SN
    Biochem Biophys Res Commun; 2013 Mar; 432(1):73-9. PubMed ID: 23376064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D; Gounarides JS; Gao J; Boettcher BR
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oleanolic acid induces a dual agonist action on PPARγ/α and GLUT4 translocation: A pentacyclic triterpene for dyslipidemia and type 2 diabetes.
    Loza-Rodríguez H; Estrada-Soto S; Alarcón-Aguilar FJ; Huang F; Aquino-Jarquín G; Fortis-Barrera Á; Giacoman-Martínez A; Almanza-Pérez JC
    Eur J Pharmacol; 2020 Sep; 883():173252. PubMed ID: 32534078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance
    Tian Y; Liu Y; Xue C; Wang J; Wang Y; Xu J; Li Z
    Food Funct; 2020 Sep; 11(9):8248-8258. PubMed ID: 32966473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.